1. Patients' perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K antagonists
- Author
-
Esther Donado, Eduardo Arellano-Rodrigo, Juan José Gómez-Doblas, Juana Umarán Sánchez, Rafael Romero Garrido, Carlos Escobar, Vivencio Barrios, Javier Pindado Rodríguez, and Jaime Fernández-Dueñas
- Subjects
Male ,medicine.medical_specialty ,Vitamin K ,030204 cardiovascular system & hematology ,Vitamin k ,Dabigatran ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Atrial Fibrillation ,medicine ,Humans ,In patient ,030212 general & internal medicine ,Prospective Studies ,business.industry ,Health Policy ,Anticoagulants ,Atrial fibrillation ,medicine.disease ,Thromboembolic risk ,Stroke ,Patient perceptions ,Multicenter study ,Female ,Perception ,business ,Previously treated ,medicine.drug - Abstract
Aim: To analyze the perception of anticoagulation with dabigatran in patients with nonvalvular atrial fibrillation previously treated with vitamin K antagonists over a 6-month period. Materials & methods: This is a prospective, noninterventional, noncontrolled, multicenter study. To assess patients’ perceptions, PACT-Q2 questionnaire was completed. Results: Six hundred and fifty nine patients (73.1 ± 9.4 years, CHA 2 DS 2 -VASc 3.6 ± 1.6) were included. At baseline, the convenience and satisfaction scores were 60.9 ± 24.9 and 49.9 ± 17.7, respectively. The scores significantly increased along the study. Convenience score was higher in males and in patients with low–moderate thromboembolic risk. Satisfaction score was higher in females. Only 8.0% of patients discontinued dabigatran (3.7% due to side effects). Conclusion: Convenience and satisfaction scores for nonvalvular atrial fibrillation patients treated with dabigatran at 6 months were significantly better than with previous vitamin K antagonists.
- Published
- 2020